Company Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD).
It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag.
The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Country | United States |
IPO Date | Jun 17, 1999 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 1,168 |
CEO | Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. |
Contact Details
Address: 1040 Spring Street Silver Spring, Maryland United States | |
Website | https://www.unither.com |
Stock Details
Ticker Symbol | UTHR |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001082554 |
CUSIP Number | 91307C102 |
ISIN Number | US91307C1027 |
Employer ID | 52-1984749 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. | Founder, Chairman & Chief Executive Officer |
James C. Edgemond | Chief Financial Officer & Treasurer |
Michael I. Benkowitz | President & Chief Operating Officer |
Dewey Steadman C.F.A. | Head of Investor Relations |
Dr. Leigh Peterson | Executive Vice President of Product Development & Xenotransplantation |
Gil Golden | Senior Vice President & Chief Medical Officer |
Holly Hobson | Associate Vice President of Human Resources |
Kevin T. Gray | Senior Vice President of Strategic Operations & Logistics |
Patrick Poisson | Executive Vice President of Technical Operations |
Paul A. Mahon J.D. | Executive Vice President, General Counsel & Corporate Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 10, 2024 | 4 | Filing |
Dec 06, 2024 | 4 | Filing |
Dec 03, 2024 | 4 | Filing |
Nov 27, 2024 | 4 | Filing |
Nov 22, 2024 | 4 | Filing |
Nov 19, 2024 | 4 | Filing |
Nov 12, 2024 | 4 | Filing |
Nov 12, 2024 | 4 | Filing |
Nov 12, 2024 | 4 | Filing |
Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |